Increased CD16 expression on NK cells is indicative of antibody-dependent cell-mediated cytotoxicity in chronic-active antibody-mediated rejection

被引:24
|
作者
Sablik, Kasia A. [1 ]
Litjens, Nicolle H. R. [1 ]
Klepper, Mariska [1 ]
Betjes, Michiel G. H. [1 ]
机构
[1] Erasmus MC, Dept Nephrol & Transplantat, Room NA2105,POB 2040, NL-3000 CA Rotterdam, Netherlands
关键词
Kidney transplantation; Biomarkers; Chronic active antibody mediated rejection; Circulating immune cells; TRANSPLANT GLOMERULOPATHY; T-CELLS; B-CELL; KIDNEY; BIOPSIES; SUBSETS; CLASSIFICATION; INFLAMMATION; TRANSCRIPTS; ACTIVATION;
D O I
10.1016/j.trim.2019.02.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chronic-active antibody mediated rejection (c-aABMR) contributes significantly to late renal allograft failure. The antibodies directed against donor-derived antigens, e.g. anti-HLA antibodies, cause inflammation at the level of the microvascular endothelium. This is characterized by signs of local activation of the complement system and accumulation of immune cells within the capillaries. Non-invasive biomarkers of c-aABMR are currently not available but could be valuable for early detection. We therefore analyzed the activation profiles of circulating T and B cells, NK cells and monocytes in the peripheral blood of 25 kidney transplant recipients with c-aABMR and compared them to 25 matched recipients to evaluate whether they could serve as a potential biomarker. No significant differences were found in the total percentage and distribution of NK cells, B cells and T cells between the c-aABMRpos and c-aABMRneg cases. There was however a higher percentage of monocytes present in c-aABMRpos cases (p < .05). Additionally, differences were found in activation status of circulating monocytes, NK cells and gamma delta T cells, mainly concerning the activation marker CD16. Although statistically significant, these differences were not sufficient for use as a biomarker of c-aABMR.
引用
收藏
页码:52 / 58
页数:7
相关论文
共 50 条
  • [21] Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection
    Gastón J Piñeiro
    Erika De Sousa-Amorim
    Manel Solé
    José Ríos
    Miguel Lozano
    Frederic Cofán
    Pedro Ventura-Aguiar
    David Cucchiari
    Ignacio Revuelta
    Joan Cid
    Eduard Palou
    Josep M Campistol
    Federico Oppenheimer
    Jordi Rovira
    Fritz Diekmann
    BMC Nephrology, 19
  • [22] The Molecular Landscape of Antibody-Mediated Kidney Transplant Rejection: Evidence for NK Involvement Through CD16a Fc Receptors
    Venner, J. M.
    Hidalgo, L. G.
    Famulski, K. S.
    Chang, J.
    Halloran, P. F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 (05) : 1336 - 1348
  • [23] Hidden Granzyme B-Mediated Injury in Chronic Active Antibody-Mediated Rejection
    Yadav, Brijesh
    Prasad, Narayan
    Agarwal, Vikas
    Agarwal, Vinita
    Jain, Manoj
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2020, 18 (07) : 778 - 784
  • [24] Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection
    Ashton-Chess, Joanna
    Le Mai, Hoa
    Jovanovic, Vojislav
    Renaudin, Karine
    Foucher, Yohann
    Giral, Magali
    Moreau, Anne
    Dugast, Emilie
    Mengel, Michael
    Racape, Maud
    Danger, Richard
    Usal, Claire
    Smit, Helga
    Guillet, Marina
    Gwinner, Wilfried
    Le Berre, Ludmilla
    Dantal, Jacques
    Soulillou, Jean-Paul
    Brouard, Sophie
    KIDNEY INTERNATIONAL, 2010, 77 (10) : 880 - 890
  • [25] Mesangiolysis in Chronic Active Antibody-mediated Rejection in Kidney Transplant Biopsies
    Suto, Yuki
    Oguchi, Hideyo
    Tochigi, Naobumi
    Mikami, Tetuo
    Shinoda, Kazunobu
    Honda, Kazuho
    Kounoue, Noriyuki
    Hashimoto, Junya
    Muramatsu, Masaki
    Itabashi, Yoshihiro
    Sakai, Ken
    NEPHRON, 2023, : 14 - 21
  • [26] Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection
    Sablik, Kasia A.
    Clahsen-van Groningen, Marian C.
    Looman, Caspar W. N.
    Damman, Jeffrey
    van Agteren, Madelon
    Betjes, Michiel G. H.
    BMC NEPHROLOGY, 2019, 20 (1)
  • [27] Preceding T-Cell-Mediated Rejection Is Associated with the Development of Chronic Active Antibody-Mediated Rejection by de Novo Donor-Specific Antibody
    Tsuji, Takahiro
    Iwasaki, Sari
    Makita, Keishi
    Imamoto, Teppei
    Ishidate, Naomichi
    Mitsuke, Akihiko
    Fukuzawa, Nobuyuki
    Harada, Hiroshi
    Fukazawa, Yuichiro
    NEPHRON, 2021, 144 (SUPPL 1) : 13 - 17
  • [28] Chronic-active antibody-mediated rejection with or without donor-specific antibodies has similar histomorphology and clinical outcome - a retrospective study
    Sablik, Kasia A.
    Clahsen-van Groningen, Marian C.
    Looman, Caspar W. N.
    Damman, Jeffrey
    Roelen, Dave L.
    van Agteren, Madelon
    Betjes, Michiel G. H.
    TRANSPLANT INTERNATIONAL, 2018, 31 (08) : 900 - 908
  • [29] Rationale for the IMAGINE study for chronic active antibody-mediated rejection (caAMR) in kidney transplantation
    Nickerson, Peter W. W.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 38 - 44
  • [30] The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
    Haas, M.
    Loupy, A.
    Lefaucheur, C.
    Roufosse, C.
    Glotz, D.
    Seron, D.
    Nankivell, B. J.
    Halloran, P. F.
    Colvin, R. B.
    Akalin, Enver
    Alachkar, N.
    Bagnasco, S.
    Bouatou, Y.
    Becker, J. U.
    Cornell, L. D.
    van Huyen, J. P. Duong
    Gibson, I. W.
    Kraus, Edward S.
    Mannon, R. B.
    Naesens, M.
    Nickeleit, V.
    Nickerson, P.
    Segev, D. L.
    Singh, H. K.
    Stegall, M.
    Randhawa, P.
    Racusen, L.
    Solez, K.
    Mengel, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 (02) : 293 - 307